Pictured left to right: Professor Michael Good AO, PDG Sandy Doumany OAM, Associate Professor Danielle Stanisic, Her Excellency the Honourable...
Hope is on the horizon for needle-phobic patients as Griffith University researchers have created a new influenza vaccine composition designed to be administered via the nose.
A next-generation COVID-19 mucosal vaccine is set to be a gamechanger not only when delivering the vaccine itself, but also for people who are needle-phobic.
Griffith researchers among 19 scientists share in $5.56 million of funding.
Griffith University’s Institute for Glycomics has received a $5 million philanthropic donation from the International Leducq Foundation to further the development of a Strep A vaccine.
Strep A (Streptococcus pyogenes) is a major cause of infection-related deaths, leading to over 500,000 fatalities annually. Developing countries, Indigenous populations, and vulnerable groups face the greatest risks. A potential vaccine, developed by Professor Michael Good's team at Griffith University, is undergoing human trials and shows promise in fighting multiple Strep A strains.
Sanofi has progressed its partnership with Griffith by officially opening its latest research site at the university’s Gold Coast campus.
As Streptococcus A cases continue to be prevalent in Queensland and internationally, a new nasal vaccine could provide long-term protection from the deadly bacteria.
A national team of experts will advance an innovative biopolymer particle-based platform technology to develop vaccine candidates to protect against biowarfare threats.
Griffith University researchers are on the brink of a technological breakthrough in vaccine development with a possible new vaccine modality.
